Cannabis and Schizophrenia: Meta-Analysis Finds Roughly Threefold Risk Elevation, but Causation Remains Contested
The cannabis schizophrenia risk meta-analysis reveals a significant association between cannabis use and increased schizophrenia risk. This risk is especially pronounced with adolescent use and high-THC products. However, causation remains contested due…
Cannabis Users Need More Propofol, But Confounders Cloud the Evidence
Cannabis anesthesia requirements are increasingly relevant as cannabis use rises among surgical patients. This meta-analysis finds cannabis users require more propofol, but confounders like age and tobacco use complicate interpretation. Understanding…
Cannabinoids for Postoperative Pain: A Systematic Review Finds Too Little Evidence to Draw Firm Conclusions
This systematic review examines cannabinoids postoperative pain evidence and finds insufficient data to support their use for acute postoperative pain. Only five randomized controlled trials were identified, with contradictory results. The review…
What the Evidence Actually Says About Cannabis: Risks, Benefits, and Lingering Uncertainties
"Chronic patterns of cannabis use have been associated with multiple adverse outcomes that are of particular concern among adolescents and young adults, such as, disrupted learning, impaired cognitive performance, reduced educational attainment and an…
Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.
Psychological interventions schizophrenia substance use are critical for treating patients with dual diagnoses. This systematic review evaluates the efficacy and acceptability of these interventions. Understanding these treatments can improve outcomes…
Cannabis and Sleep Review, Read Carefully
This paper is a systematic review and meta-analysis on recreational cannabis use and sleep in the general population. It brings together observational and experimental studies and finds that poorer sleep outcomes appear more often in observational data…
CBD’s Promise Outpaces Its Proof: A Comprehensive Review Finds Most Cannabis Products Lack Regulatory-Grade Evidence
CBD therapeutic development is advancing but regulatory-grade evidence remains limited. Most cannabis products lack robust clinical support beyond rare epilepsy syndromes. This review highlights the urgent need for rigorous trials and quality standards.
Only Five Trials Found: Cannabinoids for Post-Surgery Pain Remain an Open Question
The focus on cannabinoids acute postoperative pain reveals only five trials with contradictory results. This scarcity of data prevents meta-analytic evaluations and clinical recommendations. More standardized research is essential to clarify their role…
Common But Manageable: What a 58-Trial Meta-Analysis Reveals About Cannabis Medicine Side Effects in Older Adults
Cannabinoid adverse events older adults are dose-dependent and mostly manageable according to a 58-trial meta-analysis. THC-containing medicines increase common side effects like dizziness and dry mouth in older adults. Serious adverse events do not…
Cannabinoid Safety in Adults Over 50: Meta-Analysis Review
This meta-analysis highlights cannabinoid safety older adults, showing low adverse event rates for THC and CBD alone. Combination THC:CBD products showed higher withdrawal rates. The study emphasizes cautious use and the need for controlled trials in…